DrugPatentWatch Database Preview
DURYSTA Drug Profile
» See Plans and Pricing
Which patents cover Durysta, and what generic alternatives are available?
Durysta is a drug marketed by Allergan Inc and is included in one NDA. There are ten patents protecting this drug.
This drug has one hundred and sixty-nine patent family members in thirty-one countries.
The generic ingredient in DURYSTA is bimatoprost. There are twelve drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.
US ANDA Litigation and Generic Entry Outlook for Durysta
A generic version of DURYSTA was approved as bimatoprost by APOTEX INC on December 1st, 2014.
Summary for DURYSTA
| International Patents: | 169 |
| US Patents: | 10 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for DURYSTA |
| DailyMed Link: | DURYSTA at DailyMed |
Pharmacology for DURYSTA
| Drug Class | Prostaglandin Analog |
US Patents and Regulatory Information for DURYSTA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Allergan Inc | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for DURYSTA
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 20160077121 | Start Trial |
| China | 1950091 | Start Trial |
| Ukraine | 110696 | Start Trial |
| Spain | 2304701 | Start Trial |
| Japan | 6482547 | Start Trial |
| South Africa | 201602556 | Start Trial |
| Japan | 2010513555 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for DURYSTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0660716 | SPC/GB02/035 | United Kingdom | Start Trial | PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308 |
| 0660716 | 02C0033 | France | Start Trial | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: |
| 0660716 | C300099 | Netherlands | Start Trial | PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
